Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) is set to post its quarterly earnings results before the market opens on Wednesday, November 1st. Analysts expect Intercept Pharmaceuticals to post earnings of ($3.48) per share for the quarter.

Intercept Pharmaceuticals (NASDAQ:ICPT) last issued its quarterly earnings data on Monday, July 31st. The biopharmaceutical company reported ($3.46) earnings per share for the quarter, beating analysts’ consensus estimates of ($3.62) by $0.16. Intercept Pharmaceuticals had a negative net margin of 543.35% and a negative return on equity of 135.24%. The business had revenue of $30.89 million for the quarter, compared to analysts’ expectations of $27.50 million. During the same period in the previous year, the business earned ($3.14) earnings per share. The company’s revenue was up 459.6% on a year-over-year basis. On average, analysts expect Intercept Pharmaceuticals to post $-14.15 EPS for the current fiscal year and $-12.22 EPS for the next fiscal year.

Shares of Intercept Pharmaceuticals, Inc. (NASDAQ ICPT) opened at 61.92 on Wednesday. The company’s market capitalization is $1.55 billion. The company’s 50 day moving average is $78.07 and its 200-day moving average is $106.30. Intercept Pharmaceuticals, Inc. has a 52 week low of $54.98 and a 52 week high of $135.59.

Several equities analysts have recently issued reports on ICPT shares. Wedbush reaffirmed a “buy” rating on shares of Intercept Pharmaceuticals in a research note on Monday, July 31st. Cantor Fitzgerald reaffirmed an “underweight” rating and set a $69.00 price target (up previously from $60.00) on shares of Intercept Pharmaceuticals in a research note on Monday, July 31st. Jefferies Group LLC reaffirmed a “buy” rating and set a $275.00 price target on shares of Intercept Pharmaceuticals in a research note on Sunday, July 30th. BidaskClub raised Intercept Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, July 13th. Finally, Zacks Investment Research raised Intercept Pharmaceuticals from a “hold” rating to a “buy” rating and set a $136.00 price target on the stock in a research note on Tuesday, July 11th. Four investment analysts have rated the stock with a sell rating, ten have assigned a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company. Intercept Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $153.76.

ILLEGAL ACTIVITY NOTICE: “Intercept Pharmaceuticals, Inc. (ICPT) Scheduled to Post Earnings on Wednesday” was reported by American Banking News and is the sole property of of American Banking News. If you are reading this report on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this report can be read at https://www.americanbankingnews.com/2017/10/25/intercept-pharmaceuticals-inc-icpt-scheduled-to-post-earnings-on-wednesday.html.

In other Intercept Pharmaceuticals news, Director Daniel G. Welch sold 602 shares of the stock in a transaction dated Monday, July 31st. The stock was sold at an average price of $123.93, for a total value of $74,605.86. Following the completion of the sale, the director now directly owns 3,108 shares in the company, valued at $385,174.44. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CMO David Shapiro sold 1,118 shares of the stock in a transaction dated Tuesday, August 1st. The stock was sold at an average price of $119.00, for a total value of $133,042.00. Following the completion of the sale, the chief marketing officer now owns 45,680 shares of the company’s stock, valued at $5,435,920. The disclosure for this sale can be found here. Insiders sold 6,061 shares of company stock valued at $565,289 over the last 90 days. Corporate insiders own 4.50% of the company’s stock.

About Intercept Pharmaceuticals

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Earnings History for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.